Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)

This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or refractory MM:

• Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review Committee (SRC).
• Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding followed by cohort expansion at the combination therapy MTD or optimal dose as determined by the SRC.

Study Overview

• Status: Completed
• Conditions: Multiple Myeloma
• Intervention / Treatment: Drug: Phase 1a: CWP232291; Drug: Phase 1b: CWP232291, Lenalidomide, Dexamethasone

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Seoul National University Hospital
  • Seoul, Korea, Republic of
    • Yonsei Severance Hospital
  • Seoul, Korea, Republic of
    • Seoul St.Mary's Hospital
• United States
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Able to understand and then sign an informed consent form (ICF) prior to initiation of any study-specific procedure and treatment.
2. ≥ 18 years of age.

3. Confirmed measurable MM based on the following:

   • Serum M component (≥ 0.5 g/dL), or
   • Urine M protein ≥ 200 mg/24 hours), or
   • Serum immunoglobulin free light chains ≥ 10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio), or
   • Non-secretory disease measurable with bone marrow biopsy or radiography.
4. Failed 2 or more prior standard MM therapies, and >100 days post autologous bone marrow transplant prior to first dose for transplanted subjects. Prior lenalidomide is permitted.
5. In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be ≥ 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Persistent clinically significant toxicities from prior chemotherapy or radiotherapy must not be greater than Grade 1.
6. Eastern Cooperative Oncology Group (ECOG) performance score 0-2 (Appendix 3).

7. Adequate bone marrow function:

   • Absolute neutrophil count (ANC) ≥ 1000/mm3, independent of growth factor support;
   • Platelet count ≥ 75,000/mm3;
   • Hb ≥ 9 g/dL (independent of transfusions or erythropoiesis-stimulating agents [ESA]).

8. Adequate renal function:

   • Serum creatinine ≤ 2.5 mg/dL;
   • Creatinine clearance (CrCl) ≥ 60 mL/minute (Cockcroft-Gault).

9. Adequate hepatic function:

   • Total bilirubin < 2.5 x upper limit of normal (ULN); direct bilirubin < 2 x ULN for Gilbert's syndrome;
   • Alkaline phosphatase (AP) ≤ 2.5 x ULN, unless considered due to organ leukemic involvement;
   • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN.

11. Women of child-bearing potential (ie, women who are premenopausal or not surgically sterile):

• Two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 4 weeks after discontinuing study drugs, and
• Negative serum or urine pregnancy tests during screening and then within 3 days prior to Day 1. 12. Sexually active men - effective contraceptive methods in subject and partner from the time of informed consent and until ≥ 4 weeks after discontinuing study drugs. 13. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Chemotherapy or immunotherapy < 5 half-lives prior to screening.
2. Not recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening.
3. Systemic corticosteroids < 1 week prior to Day 1 in Phase 1a. Subjects may receive stable physiologic replacement doses of glucocorticoids (up to the equivalent of 10 mg daily prednisone) as maintenance therapy for adrenal insufficiency.
4. Uncontrolled intercurrent illness including infections and psychiatric illness/social situations that may limit compliance with protocol requirements or the evaluation of study drugs.
5. Active cardiovascular disease including myocardial infarction (MI) < 6 months of screening, symptomatic coronary artery disease (CAD), arrhythmias, hypertension, or heart failure not controlled by medication.
6. History of deep venous thrombosis and pulmonary embolism (Phase 1b).
7. Anticoagulants < 7 days prior to Day 1. Aspirin is permitted in Phase 1b per standard of care with lenalidomide-based therapy.
8. Active central nervous system (CNS) disease.
9. Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
10. Pregnant or nursing women.
11. History of hypersensitivity to lenalidomide (Part B only)
12. History of other active malignancies < 3 years prior to screening except basal cell carcinoma, low grade Gleason score ≤ 6 prostate cancer that has been removed with undetectable prostate-specific antigen (PSA), and in situ cervical carcinoma.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CWP232291; Phase 1a: single administration of CWP232291 , Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone	Drug: Phase 1a: CWP232291; CWP232291 administered alone twice weekly every 4 weeks.; Drug: Phase 1b: CWP232291, Lenalidomide, Dexamethasone; CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Recommended dose of Phase 2 trial of CWP232291	up to 4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax as a pharmacokinetic parameter of 'CWP232291'	Peak plasma concentration(Cmax) of 'CWP232291'	Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion
AUC as a pharmacokinetic parameter of 'CWP232291'	Area under the plasma concentration versus time curve (AUC) of 'CWP232291'	Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion
Cmax as a pharmacokinetic parameter of metabolites of ' CWP232204'	Peak Plasma Concentration (Cmax) of metabolites of 'CWP232291'	Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion
AUC as a pharmacokinetic parameter of metabolites of ' CWP232204'	Area under the plasma concentration versus time curve (AUC) of metabolites of 'CWP232291'	Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion

Collaborators and Investigators

• Sponsor: JW Pharmaceutical
• Investigators: Principal Investigator: Chang-Ki Min, MD, Seoul St. Mary'S Hospital; Principal Investigator: Sung-Soo Yoon, MD, Seoul National University Hospital; Principal Investigator: Jin Seok Kim, MD, Severance Hospital; Principal Investigator: Elisabet Manasanch, MD, M.D. Anderson Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): October 19, 2015
• Primary Completion (Actual): October 8, 2018
• Study Completion (Actual): October 26, 2018

Study Registration Dates

• First Submitted: April 13, 2015
• First Submitted That Met QC Criteria: April 24, 2015
• First Posted (Estimate): April 27, 2015

Study Record Updates

• Last Update Posted (Actual): May 17, 2019
• Last Update Submitted That Met QC Criteria: May 15, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Immunologic Factors; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Dexamethasone; Lenalidomide
• Other Study ID Numbers: JW-231MM-102